Incidence, Predictors and Clinical Outcomes of Stent Thrombosis Following Percutaneous Coronary Intervention in Contemporary Practice
Access Status
Authors
Date
2020Type
Metadata
Show full item recordCitation
Source Title
Additional URLs
ISSN
Faculty
School
Funding and Sponsorship
Collection
Abstract
Background: Stent thrombosis (ST) is an uncommon but serious complication of percutaneous coronary intervention (PCI). The reported rate of definite ST with new generation drug-eluting stents ranges from 0.5 to 1% at 30 days. We aimed to examine the incidence and outcomes of ST in a real-world setting. Methods: The Victorian Cardiac Outcomes Registry was established in 2012 as a state-wide clinical quality registry, with all PCI capable centres contributing in 2017. Data were collected on 41,137 consecutive PCI procedures from 2013 to 2017. We describe the patient characteristics and clinical outcomes in definite and probable ST at 30 days. Results: Stent thrombosis occurred in 225 patients (0.55%). Compared to patients without ST, these patients were more likely to be female (32.0% vs 23.4%, p≤0.01) and have a history of diabetes (28.6% vs 21.9%, p=0.02). ST was more common in patients with severely reduced left ventricular ejection fraction (14.9% vs 4.6%, p<0.001) and in patients presenting with ST-elevation myocardial infarction, cardiogenic shock and cardiac arrest for their index PCI (all p<0.001). Dual antiplatelet therapy at 30 days was less frequent in patients with ST (84.8% vs 92.0%, p<0.001), while 30-day mortality was more common: 23.6% versus 2.0% (p<0.001). Conclusions: Even with contemporary stents and adjunctive medications, ST still occurs following 1 in 200 PCIs, and is associated with increased mortality at 30 days.
Related items
Showing items related by title, author, creator and subject.
-
Yan, B.; Duffy, S.; Clark, D.; Lefkovits, J.; Warren, R.; Gurvitch, R.; Lew, R.; Sebastian, M.; Brennan, A.; Andrianopoulos, N.; Reid, Christopher; Ajani, A. (2008)Recent reports suggest that drug-eluting stents (DESs) may increase the risk of stent thrombosis (ST) relative to bare-metal stents (BMSs). Therefore, the aim of this study was to compare DES and BMS outcomes with a ...
-
Butler, M.; Eccleston, D.; Clark, D.; Ajani, A.; Andrianopoulos, N.; Brennan, A.; New, G.; Black, A.; Szto, G.; Reid, Christopher; Yan, B.; Shaw, J.; Dart, A.; Duffy, S. (2009)Background: The optimal duration of clopidogrel use for prevention of stent thrombosis with drug-eluting stent (DES) use is uncertain. Our objective was to determine whether the planned duration of clopidogrel at the time ...
-
Yan, B.; Ajani, A.; New, G.; Duffy, S.; Farouque, O.; Shaw, J.; Sebastian, M.; Lew, R.; Brennan, A.; Andrianopoulos, N.; Reid, Christopher; Clark, D. (2008)Background: Restenosis rates are low in large coronary vessels = 3.5 mm after bare-metal stent (BMS) implantation. The benefit of drug-eluting stents (DES) in large vessels is not established. Objective: We aim to assess ...